On October 25th 2014 Betta Pharmaceuticals and Xcovery reported that Xcovery will get an equity investment worth 20 million dollars from Betta Pharmaceuticals (Press release, Betta Pharmaceuticals, OCT 25, 2014, View Source;id=1492 [SID1234516487]). As the leading enterprise in new drug research and development of China, Betta continues to exert efforts in research and development of new drugs after successfully completed the development and marketing of Icotinib Hydrochloride. Located in Florida,U.S.A., Xcovery is a R&D enterprise focusing on development of new generation anti-tumor targeted drugs. Its key program, X-396, is a new generation ALK inhibitor directed at lung cancer, which is now under Phase 1/2 clinical research in the United States. Apart from equity investment, Betta will also get the development right of the X-396 program in China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!